Fri, January 24, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

Wamsi Mohan Maintained (AAPL) at Buy with Decreased Target to $253 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

Paul Lejuez Reinstated (ACI) to Buy and Held Target at $26 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

Brett Fishbin Maintained (ALC) at Overweight with Decreased Target to $105 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

David Saxon Maintained (ALC) at Buy with Decreased Target to $106 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

Gregory Renza Reiterated (AMGN) at Outperform and Held Target at $324 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

Richard Hightower Maintained (AMH) at Equal with Decreased Target to $37 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

David George Maintained (ASB) at Neutral with Decreased Target to $26 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

Karl Shepard Maintained (ASB) at Sector with Increased Target to $27 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

Adam Kramer Downgraded (AVB) to Equal and Decreased Target to $223 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

Richard Hightower Maintained (AVB) at Equal with Decreased Target to $230 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

Jason Gursky Maintained (BA) at Buy with Decreased Target to $207 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

Jared Shaw Maintained (BANC) at Overweight with Decreased Target to $19 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

David Williams Reiterated (BDC) at Buy and Held Target at $130 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

Fawne Jiang Reiterated (BIDU) at Buy and Held Target at $130 on, Jan 24th, 2025

[ Fri, Jan 24th 2025 ]: WOPRAI

Joseph Greff Maintained (BYD) at Neutral with Increased Target to $80 on, Jan 24th, 2025

Thu, January 23, 2025

[ Thu, Jan 23rd 2025 ]: MSN

Avidity Biosciences CFO sells $93,985 in stock

Michael F. MacLean, Chief Financial Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), recently sold shares of the company stock valued at approximately $93,985. The transactions occurred on January 21,

[ Thu, Jan 23rd 2025 ]: MSN

2 'Strong Buy'-Rated Dividend Stocks With Yields Above 7% for 2025

Investing in dividend stocks with a high yield of more than 7% can significantly boost your portfolio's income potential, especially in a low-interest-rate environment. However, targeting companies with sustainable dividend payouts is crucial,

[ Thu, Jan 23rd 2025 ]: MSN

Altimmune's SWOT analysis: pemvidutide potential drives stock outlook

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on developing treatments for liver disease and obesity, has been garnering attention from analysts and investors alike.

[ Thu, Jan 23rd 2025 ]: MSN

Diamondback Energy's SWOT analysis: stock poised for growth amid merger synergies

Diamondback Energy Inc (NASDAQ:FANG), a leading independent oil and gas company focused on the Permian Basin with a market capitalization of $51.48 billion, has been making significant strides in operational efficiency and strategic growth.

[ Thu, Jan 23rd 2025 ]: Forbes

S&P 500 Index Funds: Risks You Must Know Before You Invest

Low cost S&P 500 index funds are fantastic investment vehicles but they are not without risks. We discuss these risks and how to best think about them.

[ Thu, Jan 23rd 2025 ]: MSN

Are famous short-sellers going extinct? The exit of Hindenburg Research and Andrew Left shows the risky trade is shrinking

The exposé led to the company's CEO going to jail and to Anderson's short-selling firm, Hindenburg Research, becoming one of the most feared names in corporate America. When Anderson announced last Wednesday that Hindenburg was closing shop,

[ Thu, Jan 23rd 2025 ]: MSN

Is AbbVie Inc. (ABBV) the Best Halal Dividend Stock to Invest In Now?

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other halal dividend stocks.

[ Thu, Jan 23rd 2025 ]: MSN

Is Intel Corporation (INTC) One of the Best Socially Responsible Stocks to Buy According to Hedge Funds?

We recently compiled a list of the 8 Best Socially Responsible Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Intel Corporation (NASDAQ:INTC) stands against other best socially responsible stocks to buy according to hedge funds.

[ Thu, Jan 23rd 2025 ]: Forbes

Is Quantum Computing Investable As The Next AI

Quantum computing has the potential of being the next big innovation. At the right size and the right price, it might even be investable.

[ Thu, Jan 23rd 2025 ]: MSN

Is Johnson & Johnson (JNJ) the Best Halal Dividend Stock to Invest In Now?

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other halal dividend stocks.

[ Thu, Jan 23rd 2025 ]: MSN

BlackRock CEO Fink advocates for tokenization of stocks and bonds

In a recent public statement, Larry Fink, the Chief Executive Officer of BlackRock (NYSE:BLK), expressed his support for the Securities and Exchange Commission (SEC) to approve the tokenization of bonds and stocks.

[ Thu, Jan 23rd 2025 ]: MSN

Is PepsiCo, Inc. (PEP) the Best Halal Dividend Stock to Invest In Now?

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look at where PepsiCo, Inc. (NASDAQ:PEP) stands against the other halal dividend stocks.

[ Thu, Jan 23rd 2025 ]: AOL

Warren Buffett: 5 Stocks He's Dead Serious About In 2025

Warren Buffett, the legendary investor known as the "Oracle of Omaha," continues to make waves in the financial world even as he approaches his mid-90s. His company, Berkshire Hathaway, has been

[ Thu, Jan 23rd 2025 ]: MSN

Is Medtronic plc (MDT) the Best Halal Dividend Stock to Invest In Now?

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look at where Medtronic plc (NYSE:MDT) stands against the other halal dividend stocks.

[ Thu, Jan 23rd 2025 ]: Forbes

What Are The Risks Of S&P 500 Index Funds?

Low cost S&P 500 index funds are fantastic investment vehicles but they are not without risks. We discuss these risks and how to best think about them.

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of EYPT at $8.86, after crossing above the $8.78 Trigger Price

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of FMAO at $26.27, after crossing above the $26.264 Trigger Price

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of PLAY at $27.74, after crossing above the $27.587 Trigger Price

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of CHGCF at $44.22, after crossing above the $44.189 Trigger Price

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of ACIC at $12.2, after crossing above the $12.149 Trigger Price

[ Thu, Jan 23rd 2025 ]: MSN

How to Get Your Kids into Investing: A Family Project to Try

To teach your children about investing, put your money where your mouth is with this fun and potentially profitable exercise.

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of TENB at $42.81, after crossing above the $42.514 Trigger Price

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of UGI at $30.349, after crossing above the $30.301 Trigger Price

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of SD at $12.4, after crossing above the $12.372 Trigger Price

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of PHG at $26.52, after crossing above the $26.497 Trigger Price

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of LVO at $1.25, after crossing above the $1.222 Trigger Price

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of IVDN at $0.32, after crossing above the $0.277 Trigger Price

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of FMS at $24.31, after crossing above the $23.655 Trigger Price

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of BWB at $13.545, after crossing above the $13.387 Trigger Price

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of BUSE at $23.04, after crossing above the $22.952 Trigger Price

[ Thu, Jan 23rd 2025 ]: MSN

Dave Ramsey: If You Invested $10K in These Companies, You'd Be Nearly $16K Richer

Unlike many finance experts and investors, Dave Ramsey does not recommend investing in S&P 500 stocks. You won't see names like Apple or Amazon in his portfolio -- at least not directly.

[ Thu, Jan 23rd 2025 ]: MSN

The Worst Mistakes Almost Every TFSA Holder Makes, and the CRA Is Watching

The TFSA is great, sure, but these mistakes could be keeping you from creating cash. The post The Worst Mistakes Almost Every TFSA Holder Makes, and the CRA Is Watching appeared first on The Motley Fool Canada.

[ Thu, Jan 23rd 2025 ]: WOPRAI

Short squeeze is starting in shares of TXO at $19.41, after crossing above the $19.19 Trigger Price

Altimmune's SWOT analysis: pemvidutide potential drives stock outlook

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on developing treatments for liver disease and obesity, has been garnering attention from analysts and investors alike.

The article from MSN Money discusses Altimmune, Inc., a clinical-stage biopharmaceutical company, focusing on its SWOT analysis and the potential impact of its lead product candidate, pemvidutide, on its stock outlook. Pemvidutide is a GLP-1/glucagon dual receptor agonist aimed at treating obesity and non-alcoholic steatohepatitis (NASH). Strengths include a promising pipeline with pemvidutide showing significant weight loss in early trials, and a robust intellectual property portfolio. Weaknesses highlight the company's reliance on the success of pemvidutide, with no other products currently generating revenue, and its history of net losses. Opportunities are vast, given the growing market for obesity and NASH treatments, potential partnerships, and the possibility of expanding into other metabolic diseases. Threats include intense competition from larger pharmaceutical companies, potential clinical trial failures, and regulatory hurdles. The article suggests that while pemvidutide's potential could drive stock value, investors should consider the inherent risks associated with clinical-stage biotech companies.

Read the Full MSN Article at:
https://www.msn.com/en-us/money/general/altimmune-s-swot-analysis-pemvidutide-potential-drives-stock-outlook/ar-AA1xLijY